FI4070800T3 - Kladribiinikuuri multippeliskleroosin hoitoa varten - Google Patents
Kladribiinikuuri multippeliskleroosin hoitoa varten Download PDFInfo
- Publication number
- FI4070800T3 FI4070800T3 FIEP22166610.0T FI22166610T FI4070800T3 FI 4070800 T3 FI4070800 T3 FI 4070800T3 FI 22166610 T FI22166610 T FI 22166610T FI 4070800 T3 FI4070800 T3 FI 4070800T3
- Authority
- FI
- Finland
- Prior art keywords
- cladribine
- pharmaceutical formulation
- months
- use according
- effective dose
- Prior art date
Links
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 title claims 64
- 229960002436 cladribine Drugs 0.000 title claims 64
- 201000006417 multiple sclerosis Diseases 0.000 title claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 230000006698 induction Effects 0.000 claims 10
- 238000012423 maintenance Methods 0.000 claims 6
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 2
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63866904P | 2004-12-22 | 2004-12-22 | |
| EP04106909 | 2004-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4070800T3 true FI4070800T3 (fi) | 2025-01-14 |
Family
ID=36227798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP22166610.0T FI4070800T3 (fi) | 2004-12-22 | 2005-12-20 | Kladribiinikuuri multippeliskleroosin hoitoa varten |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7713947B2 (https=) |
| EP (7) | EP3332789B1 (https=) |
| JP (7) | JP5795456B2 (https=) |
| KR (1) | KR20070091662A (https=) |
| AR (1) | AR052830A1 (https=) |
| AU (2) | AU2005318190B2 (https=) |
| BR (1) | BRPI0517132B8 (https=) |
| CA (2) | CA3087419C (https=) |
| CY (3) | CY1112614T1 (https=) |
| DK (3) | DK3332789T3 (https=) |
| EA (1) | EA015799B1 (https=) |
| ES (2) | ES3007339T3 (https=) |
| FI (1) | FI4070800T3 (https=) |
| FR (1) | FR18C1008I2 (https=) |
| HR (1) | HRP20120228T1 (https=) |
| HU (3) | HUE059133T2 (https=) |
| IL (2) | IL183930A0 (https=) |
| LT (3) | LT3332789T (https=) |
| LU (1) | LUC00064I2 (https=) |
| MX (1) | MX2007007610A (https=) |
| NO (1) | NO20073813L (https=) |
| PL (4) | PL3332789T3 (https=) |
| SG (1) | SG160391A1 (https=) |
| SI (3) | SI4070800T1 (https=) |
| WO (1) | WO2006067141A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3332789B1 (en) | 2004-12-22 | 2022-04-06 | Merck Serono SA | Cladribine regimen for treating multiple sclerosis |
| AU2007253254B2 (en) * | 2006-05-24 | 2013-01-17 | Merck Serono Sa | Cladribine regimen for treating multiple sclerosis |
| EP2343074A1 (en) | 2009-12-23 | 2011-07-13 | Merck Serono S.A. | Use of purine analogues for treating airway diseases |
| WO2011117267A1 (en) | 2010-03-24 | 2011-09-29 | Merck Serono Sa | Cladribine treatment of multiple sclerosis in patient groups defined by genotype |
| EP2428201A1 (en) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Oral administration of nucleoside monophosphates |
| WO2012097867A1 (en) | 2011-01-18 | 2012-07-26 | Synthon Bv | Cladribine particles and pharmaceutical compositions comprising them |
| GB201401465D0 (en) * | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
| GB2564717A (en) | 2017-07-21 | 2019-01-23 | Chord Therapeutics S A R L | Use of cladribine for treating autoimmune neuromuscular disease |
| EP3713582A1 (en) * | 2017-11-24 | 2020-09-30 | Merck Patent GmbH | Cladribine regimen for use intreating progressive forms of multiple sclerosis |
| CA3194812A1 (en) | 2020-09-10 | 2022-03-17 | Merck Patent Gmbh | Novel treatment regimen for the treatment of autoimmune disorders |
| GB2601786A (en) | 2020-12-10 | 2022-06-15 | Chord Therapeutics S A R L | Use of cladribine for treating immune brain disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1269659A (en) | 1984-08-06 | 1990-05-29 | Brigham Young University | Method for the production of 2'-deoxyadenosine compounds |
| US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US4964848A (en) * | 1988-06-27 | 1990-10-23 | Bloom Philip M | Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression |
| US5208327A (en) | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5641757A (en) | 1994-12-21 | 1997-06-24 | Ortho Pharmaceutical Corporation | Stable 2-chloro-2'-deoxyadenosine formulations |
| ES2182920T3 (es) | 1994-12-22 | 2003-03-16 | Ortho Pharma Corp | Formulaciones solubles de 2-cloro02'-deoxiadenosina. |
| US6194395B1 (en) | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| WO2000064918A1 (en) | 1999-04-28 | 2000-11-02 | Sterrenbeld Biotechnologie North America, Inc. | METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE |
| DE10237146A1 (de) * | 2002-08-13 | 2004-03-04 | Medac Gesellschaft für klinische Spezialpräparate mbH | Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose |
| ES2405825T3 (es) | 2002-09-25 | 2013-06-03 | Brigham Young University | Método para la preparación de compuestos 2-halo-2'-desoxiadenosina a partir de 2'-desoxiguanosina |
| GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| AU2004216485B2 (en) * | 2003-02-25 | 2009-06-11 | Merck Serono Sa | Combined use of ribavirin and interferon beta in demyelinating diseases |
| HRP20050924A2 (en) | 2003-03-28 | 2006-08-31 | Ivax Corporation | Cladribine formulations for improved oral and transmucosal delivery |
| ES2409884T3 (es) * | 2003-03-28 | 2013-06-28 | Ares Trading S.A. | Formulaciones orales de cladribina |
| EP3332789B1 (en) | 2004-12-22 | 2022-04-06 | Merck Serono SA | Cladribine regimen for treating multiple sclerosis |
| AU2007253254B2 (en) * | 2006-05-24 | 2013-01-17 | Merck Serono Sa | Cladribine regimen for treating multiple sclerosis |
-
2005
- 2005-12-20 EP EP18151634.5A patent/EP3332789B1/en not_active Expired - Lifetime
- 2005-12-20 EP EP24206496.2A patent/EP4523753A3/en not_active Withdrawn
- 2005-12-20 DK DK18151634.5T patent/DK3332789T3/da active
- 2005-12-20 DK DK14001970.4T patent/DK2805723T3/da active
- 2005-12-20 MX MX2007007610A patent/MX2007007610A/es unknown
- 2005-12-20 ES ES22166610T patent/ES3007339T3/es not_active Expired - Lifetime
- 2005-12-20 HR HR20120228T patent/HRP20120228T1/hr unknown
- 2005-12-20 LT LTEP18151634.5T patent/LT3332789T/lt unknown
- 2005-12-20 HU HUE18151634A patent/HUE059133T2/hu unknown
- 2005-12-20 PL PL18151634.5T patent/PL3332789T3/pl unknown
- 2005-12-20 CA CA3087419A patent/CA3087419C/en not_active Expired - Lifetime
- 2005-12-20 DK DK22166610.0T patent/DK4070800T3/da active
- 2005-12-20 SG SG201001736-6A patent/SG160391A1/en unknown
- 2005-12-20 EP EP14001970.4A patent/EP2805723B1/en not_active Revoked
- 2005-12-20 KR KR1020077016508A patent/KR20070091662A/ko not_active Ceased
- 2005-12-20 PL PL22166610.0T patent/PL4070800T3/pl unknown
- 2005-12-20 ES ES18151634T patent/ES2921858T3/es not_active Expired - Lifetime
- 2005-12-20 CA CA2588966A patent/CA2588966C/en not_active Expired - Lifetime
- 2005-12-20 EP EP10182676.6A patent/EP2263678B1/en not_active Expired - Lifetime
- 2005-12-20 US US11/722,018 patent/US7713947B2/en active Active
- 2005-12-20 EA EA200701221A patent/EA015799B1/ru active Protection Beyond IP Right Term
- 2005-12-20 PL PL14001970T patent/PL2805723T3/pl unknown
- 2005-12-20 BR BRPI0517132A patent/BRPI0517132B8/pt active IP Right Grant
- 2005-12-20 AU AU2005318190A patent/AU2005318190B2/en not_active Expired
- 2005-12-20 EP EP05823474A patent/EP1827461B1/en not_active Expired - Lifetime
- 2005-12-20 JP JP2007547486A patent/JP5795456B2/ja not_active Expired - Lifetime
- 2005-12-20 SI SI200532321T patent/SI4070800T1/sl unknown
- 2005-12-20 WO PCT/EP2005/056954 patent/WO2006067141A1/en not_active Ceased
- 2005-12-20 EP EP22166610.0A patent/EP4070800B1/en not_active Revoked
- 2005-12-20 EP EP10182632.9A patent/EP2275110B1/en not_active Expired - Lifetime
- 2005-12-20 HU HUE22166610A patent/HUE070333T2/hu unknown
- 2005-12-20 SI SI200532191T patent/SI2805723T1/en unknown
- 2005-12-20 SI SI200532305T patent/SI3332789T1/sl unknown
- 2005-12-20 LT LTEP22166610.0T patent/LT4070800T/lt unknown
- 2005-12-20 FI FIEP22166610.0T patent/FI4070800T3/fi active
- 2005-12-20 PL PL05823474T patent/PL1827461T3/pl unknown
- 2005-12-21 AR ARP050105411A patent/AR052830A1/es not_active Application Discontinuation
-
2007
- 2007-06-14 IL IL183930A patent/IL183930A0/en active IP Right Grant
- 2007-07-20 NO NO20073813A patent/NO20073813L/no not_active Application Discontinuation
-
2010
- 2010-04-23 US US12/766,173 patent/US8377903B2/en active Active
-
2011
- 2011-02-23 AU AU2011200768A patent/AU2011200768B2/en not_active Expired
- 2011-04-17 IL IL212421A patent/IL212421A/en active IP Right Grant
-
2012
- 2012-04-11 CY CY20121100358T patent/CY1112614T1/el unknown
-
2013
- 2013-05-30 JP JP2013113850A patent/JP5908863B2/ja not_active Expired - Lifetime
-
2015
- 2015-06-16 JP JP2015120875A patent/JP6092945B2/ja not_active Expired - Lifetime
-
2016
- 2016-04-08 JP JP2016078293A patent/JP6290962B2/ja not_active Expired - Lifetime
-
2017
- 2017-02-09 JP JP2017022375A patent/JP6430554B2/ja not_active Expired - Lifetime
-
2018
- 2018-01-18 CY CY20181100065T patent/CY1119790T1/el unknown
- 2018-02-12 LU LU00064C patent/LUC00064I2/fr unknown
- 2018-02-14 FR FR18C1008C patent/FR18C1008I2/fr active Active
- 2018-02-15 HU HUS1800009C patent/HUS1800009I1/hu unknown
- 2018-02-20 LT LTPA2018503C patent/LTC2805723I2/lt unknown
- 2018-02-28 CY CY2018006C patent/CY2018006I1/el unknown
- 2018-07-09 JP JP2018129918A patent/JP2018165271A/ja active Pending
-
2020
- 2020-08-06 JP JP2020134010A patent/JP2020193206A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5251419A1 (es) | Composiciones nanoparticuladas de eplerenona | |
| Oronsky et al. | A review of clinical radioprotection and chemoprotection for oral mucositis | |
| EA200900264A1 (ru) | Композиции флибансерина и способ их приготовления | |
| HRP20151350T1 (hr) | Neuroprotekcija kod demijelinizacijskih bolesti | |
| FI4070800T3 (fi) | Kladribiinikuuri multippeliskleroosin hoitoa varten | |
| CA2240329A1 (en) | Improved delivery of multiple doses of medications | |
| JP2013231087A5 (https=) | ||
| JP2012180381A5 (https=) | ||
| IL300151A (en) | Combinations for cancer treatment | |
| PT1411921E (pt) | Composições farmacêuticas contendo terbinafina e suas utilizações | |
| CA2494015A1 (en) | Antibiotic product, use and formulation thereof | |
| JP2009511590A5 (https=) | ||
| NO20080244L (no) | Doseringsstyring for prasugrel | |
| AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
| BR0013719A (pt) | Dosagem oral de liberaçâo controlada, apropriada para administração oral | |
| CA2563058C (en) | Supportive treatment of liver disease | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| JP2021502347A5 (https=) | ||
| HRP20050824B1 (hr) | Komplet za farmaceutsku upotrebu | |
| MD2549F1 (en) | Method of treatment of the chronic viral hepatitis C | |
| MX354080B (es) | Tratamiento de la esclerosis multiple (em) con campath 1h. | |
| JP2019522030A5 (https=) | ||
| JP2004534821A5 (https=) | ||
| JP2011513315A5 (https=) | ||
| WO2007145993A3 (en) | Modified compositions and methods for enhancing brain function |